FLINT, Mich., March 28, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO) will have access to dispense
DUPIXENT® (dupilumab), recently approved by the Food and
Drug Administration to treat adult patients who have inadequately
controlled moderate-to-severe atopic dermatitis.
To learn more about Diplomat's dermatology program, visit
diplomat.is/areas-of-excellence/dermatology.
Atopic dermatitis (AD), the most common form of eczema, is an
inflammatory disease characterized by itchy, inflamed skin.
According to the National Institutes of Health, it affects
approximately 30 percent of people in the
United States. DUPIXENT® is a monoclonal antibody
that works with the immune system and has demonstrated improved
signs and symptoms in adult patients with inadequately controlled
moderate-to-severe AD.
"Moderate-to-severe atopic dermatitis is a debilitating,
life-altering disease with very limited treatment options," said
Paul Urick, Diplomat's president.
"We are thrilled to offer this new option for patients with unmet
needs."
DUPIXENT® is administered through subcutaneous
injection.
DUPIXENT® is co-developed by Sanofi and Regeneron
Pharmaceuticals, Inc. For full prescribing information, click
here.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50
states. Headquartered in Flint,
Michigan, the company focuses on medication management
programs for people with complex chronic diseases. Diplomat opened
its doors in 1975 as a neighborhood pharmacy with one essential
tenet: "Take good care of patients and the rest falls into place."
Today, that tradition continues—always focused on improving patient
care and clinical adherence. For more information, visit
diplomat.is.
CONTACT:
Kali Lucas, Public Relations
Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-dupixent-to-treat-atopic-dermatitis-300430710.html
SOURCE Diplomat Pharmacy, Inc.